StockNews.com upgraded shares of Haemonetics (NYSE:HAE – Get Rating) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday. Several other research firms also recently commented on HAE. Morgan Stanley upped their price objective on shares of Haemonetics from $84.00 to $88.00 and gave the company an equal […]